Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.

Fiche publication

Date publication

février 2025

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MARTIN Etienne

Tous les auteurs :
Vera P, Giraud P, Hapdey S, Gouel P, Jan O, Le Roux P, Langlais A, Lévêque E, Le Tinier F, Olivier A, Martin E, Berriolo-Riedinger A, Pourel N, Broglia JM, Boisselier P, Guillemard S, Salem N, Brenot-Rossi I, Garcia C, Berthold C, Giroux-Leprieur E, Moreau D, Guillerm S, Benali K, Tessonnier L, Audigier-Valette C, Lerouge D, Quak E, Massabeau C, Courbon F, Loo M, Larrouy A, Ghazzar N, Chaumet-Riffaud P, Amour E, Zalcman G, Modzelewski R, Thureau S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40015915

Résumé

The purpose of this study was to assess the prognostic value of F-FDG PET parameter variation between baseline and 42 Gy (PET2) of radiochemotherapy at 6 mo and 1 y of evaluation in patients with stage III inoperable nonsmall cell lung cancer based on RECIST 1.1. In total, 158 patients in a prospective multicenter phase II/III study were analyzed. Patients were randomized into 2 groups: an experimental arm (group A) and a standard arm (group B). Patients from group A with residual metabolism on PET2 (group A+) at 42 Gy received a radiation boost (74 Gy). Patients without residual uptake on F-FDG PET at 42 Gy (group A-) and patients in group B received a standard radiotherapy dose (66 Gy). We compared group A with group B. The F-FDG PET parameters SUV, SUV, SUV, peak SUV normalized on lean body mass, mean SUV normalized on lean body mass, total lesion glycolysis, total metabolic tumor volume (MTV) (tumor and nodes), and tumor MTV were measured. All patients were evaluated with RECIST 1.1 using CT at 6 mo and 1 y after radiochemotherapy. Progression-free survival and overall survival were evaluated. Except for the radiotherapy dose ( < 0.001), patient demographic characteristics were similar between the 2 groups (A vs. B). All F-FDG PET uptake and volume parameter measurements were correlated. Therefore, only the change in SUV (ΔSUV) and total MTV were selected for the analysis. There was no significant difference in any variable between the 2 groups. In the multivariate analysis, ΔSUV appeared to be the most important prognostic factor for overall survival, and SUV of PET2 appeared to be the most important prognostic factor for progression-free survival. F-FDG PET at 42 Gy can be used to identify good responders to radiochemotherapy in patients with inoperable stage III nonsmall cell lung cancer. The SUV of PET2 and ΔSUV are independent prognostic factors.